Sign up for additional communications

Enter your information below, and you will receive information about XIFAXAN (rifaximin) 550 mg. All personal information will be kept confidential and will not be shared with any parties other than Salix Pharmaceuticals and its designated partners.

*= required.

To complete your registration, we ask you take a moment to read the below information to better understand how Salix Pharmaceuticals uses the information you provided us. When you finish reading, please check the “I Agree” box and confirm your age. Then click SUBMIT to complete your registration.

Salix Pharmaceuticals respects the importance of your privacy and understands your health is a very personal and sensitive subject. Salix Pharmaceuticals wants you to understand how it will use the information provided by you on this registration page. By clicking “I Agree” below, you are indicating you want to learn more about this service and receive promotional or non-promotional updates via email or mail from Salix Pharmaceuticals or its partners about products, support services, or other special opportunities that Salix Pharmaceuticals or its partners believe might be interesting to you. You also understand that you may opt out from receiving any future communications from Salix Pharmaceuticals or its partners by clicking the “unsubscribe” link within any email you receive, by calling 1-866-XIFAXAN, or by sending us a letter containing your full contact information (e.g. name, email address, phone) to 200 South Jefferson Road, Whippany, NJ 07981.

To better understand how Salix Pharmaceuticals values your privacy and what other information may collected from you while you use this service, please see our Privacy Policy.

All personal information will be kept confidential and will not be shared with any parties other than Salix Pharmaceuticals and its designated partners. Click here to view our full Privacy Policy.

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.